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Introduction {#cam41503-sec-0001}
============

Breast cancer is the most common cancer in women, and its incidence is increasing annually worldwide [1](#cam41503-bib-0001){ref-type="ref"}, [2](#cam41503-bib-0002){ref-type="ref"}. Breast cancer is also a heterogeneous disease, divisible into various clinical subtypes, and the pathogenesis is not clear [3](#cam41503-bib-0003){ref-type="ref"}. As early as the 1970s, De Waard proposed the concept that breast cancers develop by two distinct pathways, each with a different age‐specific incidence rate curve [4](#cam41503-bib-0004){ref-type="ref"}, [5](#cam41503-bib-0005){ref-type="ref"}. The first pathway results in mainly premenopausal tumors with peak occurrence early in life. The second pathway results in predominantly postmenopausal cancers with peak incidence later in life, similar to late‐onset estrogen receptor(ER)‐positive cancers.

In China, the data from both Shanghai and Beijing showed two breast cancer age peaks, one at 45--55 years and the other at 70--74 years [6](#cam41503-bib-0006){ref-type="ref"}. The mean age at diagnosis of breast cancer in China is 45--55 years, which is considerably younger than that for western women, with 57.4% of women diagnosed before the age of 50 years and 62.9% of women diagnosed while still premenopausal; the peak incidence occurred after menopause in developed countries [7](#cam41503-bib-0007){ref-type="ref"}. This result suggests the possibility that certain differences in the pathogenesis of breast cancer may exist between Chinese women and women in Western populations.

Few studies have investigated the risk factors that may influence the age at diagnosis of breast cancer. The difference in the clinicopathologic features and treatment modes between premenopausal and postmenopausal patients with breast cancer is not known. Some scholars have predicted that the incidence of hormone receptor‐positive breast cancer is affected by the menopause transition [8](#cam41503-bib-0008){ref-type="ref"}, [9](#cam41503-bib-0009){ref-type="ref"}. Nonetheless, and somewhat paradoxically, it has been reported that menopause significantly affects the incidence of ER‐negative breast cancer but not that of ER‐positive breast cancer [10](#cam41503-bib-0010){ref-type="ref"}, [11](#cam41503-bib-0011){ref-type="ref"}. Presently, this issue is controversial.

Currently, no study has compared the difference between premenopausal and postmenopausal breast cancers in China. Therefore, the main objective of this study was to assess the epidemiological characteristics, clinicopathologic features, and treatment modes between premenopausal and postmenopausal breast cancers to make treatment decisions and improve patient prognoses, as well as to provide valuable insights into what may influence the age at diagnosis of breast cancer in western China.

Materials and Methods {#cam41503-sec-0002}
=====================

Study design {#cam41503-sec-0003}
------------

The Western China Clinical Cooperation Group (WCCCG) was established in 2008 and includes 23 breast cancer centers in nine provinces in western China. A total of 18,000 patients with breast cancer are included in the database. Male patients and female patients without menopausal status and age at diagnosis were excluded from the study. In total, 15,389 patients with breast cancer who were diagnosed between 1 January 2009 and 30 April 2017 were included in the retrospective multicenter database analysis. Among them, 8395 patients (54.55%) were divided into premenopausal group, and 6994 patients (45.45%) were divided into postmenopausal group. This observational study was based entirely on data extracted from patient medical records and was approved by the ethics committee of each participating center.

Patients {#cam41503-sec-0004}
--------

The data for this study, including demographic data and tumor data, were extracted from the medical records of the patients included herein by trained data collectors at each center and were analyzed anonymously.

Data collection {#cam41503-sec-0005}
---------------

Demographic data included information regarding the age at diagnosis, race, age at menarche, marital status, and number of pregnancies, number of births, breastfeeding history, and body mass index. Clinical characteristics consisted of tumor laterality, location in the breast, axillary and supraclavicular lymph node status, and size in cm. The tumors were classified according to initial disease symptoms and signs and whether there was distant metastasis in the body. The following pathologic characteristics were evaluated in the study: tumor histological types, axillary lymph node metastases, numbers of positive axillary lymph nodes, the presence of lymph vascular invasion, tumor grade, ER and PR status, HER2 and P53 expression, and Ki67 status. Data regarding treatments were also collected and included the chemotherapy regimens, radiotherapy regimens, anti‐HER2 therapy regimens, endocrine therapy regimens, types of surgeries, and axillary lymph node dissection procedures.

Pathological grading and staging criteria {#cam41503-sec-0006}
-----------------------------------------

The tumor was graded according to the Bloom--Richardson classification (Nottingham grading) [12](#cam41503-bib-0012){ref-type="ref"}. Staging of breast cancer size was performed according to the American Joint Committee on Cancer (AJCC) TNM staging system (from 1997 and 2002) [13](#cam41503-bib-0013){ref-type="ref"}. All centers use the same criteria.

Statistical analyses {#cam41503-sec-0007}
--------------------

Statistical analyses were performed using the Statistical Package for the Social Sciences, version 22.0 (SPSS Inc., Chicago, IL, USA). The differences in the demographic, clinical, and pathological characteristics and in treatments between the two groups were analyzed using Student\'s *t*‐test in the case of quantitative variables and chi‐square tests and Fisher\'s exact test in the case of categorical variables. Multivariate logistic regression analyses were performed to assess the associations between menopausal status and several variables, and odds ratios (ORs) were calculated based on 95% confidence intervals. Variables with univariate results of *P* \< 0.05 were included in the multivariate model. All statistical tests were considered significant when *P* \< 0.05.

Results {#cam41503-sec-0008}
=======

Comparison of the baseline characteristics {#cam41503-sec-0009}
------------------------------------------

The comparison of the baseline characteristics of premenopausal and postmenopausal groups is summarized in Table [1](#cam41503-tbl-0001){ref-type="table-wrap"}. The mean ages at diagnosis of the patients in premenopausal and postmenopausal groups were 42.8 and 58.2 years, respectively, and there was a difference in the distributions of the ages at which patients were diagnosed between the two groups (*P* \< 0.0001). The proportion of patients of Han ethnicity was lower in premenopausal group than in postmenopausal group (94.69% vs. 96.61%, respectively, *P* \< 0.0001). Most of the patients in the two groups experienced menarche at 13--14 years \[*n* = 4396 (52.36%) and *n* = 3456 (49.41%), respectively\]. Patients in premenopausal group were younger at the time of menarche (younger than 12 years) than patients in postmenopausal group. In addition, more patients in postmenopausal group experienced menarche at an age older than 15 years (*P* \< 0.0001).We also observed differences in the marital status (*P* \< 0.0001), number of pregnancies (*P* \< 0.0001), number of births (*P* = 0.002), and breastfeeding history (*P* \< 0.0001) between the two groups. The mean body mass indexes (BMI) of the patients in premenopausal and postmenopausal groups were 23.1 and 23.6, respectively. An analysis of BMI showed that premenopausal group included more patients who had a BMI \<25.0 compared with that postmenopausal group \[*n* = 3693 (43.99%) and *n* = 2825 (40.39%), respectively\] (*P* \< 0.0001).

###### 

Baseline characteristics of the patients with breast cancer

  Characteristics           Total (*N* = 15,389)   Premenopausal (*N* = 8395)   Postmenopausal (*N* = 6994)   *P* value                        
  ------------------------- ---------------------- ---------------------------- ----------------------------- ----------- ------------ ------- -------------------------------------------------
  Age                                                                                                                                          
  Mean ± SD                 49.6 ± 11.1                                         42.8 ± 7.0                                58.2 ± 8.5           \<0.0001[a](#cam41503-note-0003){ref-type="fn"}
  Race/ethnicity                                                                                                                               
  Han                       14,706                 95.51                        7949                          94.69       6757         96.61   \<0.0001[b](#cam41503-note-0004){ref-type="fn"}
  Other                     683                    4.44                         446                           5.31        237          3.39    
  Age at menarche (years)                                                                                                                      
  ≤10                       30                     0.19                         20                            0.24        10           0.14    \<0.0001[b](#cam41503-note-0004){ref-type="fn"}
  11--12                    1844                   11.98                        1191                          14.19       653          9.34    
  13--14                    7852                   50.99                        4396                          52.36       3456         49.41   
  15--16                    3981                   25.85                        2089                          24.88       1892         27.05   
  17--18                    1349                   8.76                         583                           6.94        766          10.95   
  ≥19                       284                    1.84                         98                            1.17        186          2.66    
  Missing data              49                     0.32                         18                            0.21        31           0.44    
  Marital status                                                                                                                               
  Married                   14,960                 97.16                        8188                          97.53       6772         96.83   \<0.0001[c](#cam41503-note-0005){ref-type="fn"}
  Never married             138                    0.90                         110                           1.31        28           0.40    
  Widowed/divorced          276                    1.79                         89                            1.06        187          2.67    
  Missing data              15                     0.10                         8                             0.10        7            0.10    
  Number of pregnancies                                                                                                                        
  0                         3239                   21.04                        1790                          21.32       1449         20.72   \<0.0001[b](#cam41503-note-0004){ref-type="fn"}
  1                         3848                   24.99                        2216                          26.40       1632         23.33   
  2                         3228                   20.96                        1807                          21.52       1421         20.32   
  3                         2228                   14.47                        1230                          14.65       998          14.27   
  4                         1408                   9.14                         715                           8.52        693          9.91    
  ≥5                        1413                   9.18                         623                           7.42        790          11.30   
  Missing data              25                     0.16                         14                            0.17        11           0.16    
  Number of births                                                                                                                             
  0                         2753                   17.88                        1584                          18.87       1169         16.71   \<0.0001[b](#cam41503-note-0004){ref-type="fn"}
  1                         7086                   46.02                        4404                          52.46       2682         38.35   
  2                         3579                   23.24                        1887                          22.48       1692         24.19   
  3                         1198                   7.78                         378                           4.50        820          11.72   
  4                         468                    3.04                         97                            1.16        371          5.30    
  ≥5                        282                    1.83                         32                            0.38        250          3.57    
  Missing data              23                     0.15                         13                            0.15        10           0.14    
  Breastfeeding history                                                                                                                        
  No                        1543                   10.02                        900                           10.72       643          9.19    0.002[b](#cam41503-note-0004){ref-type="fn"}
  Yes                       5050                   32.80                        2685                          31.98       2365         33.81   
  Missing data              8796                   57.12                        4810                          57.30       3986         56.99   
  BMI                                                                                                                                          \<0.0001[a](#cam41503-note-0003){ref-type="fn"}
  Mean ± SD                 23.3 ± 2.5                                          23.1 ± 2.4                                23.6 ± 2.7           \<0.0001[b](#cam41503-note-0004){ref-type="fn"}
  \<18.5                    442                    2.87                         252                           3.00        190          2.72    
  18.5\~24.9                6076                   39.46                        3441                          40.99       2635         37.68   
  25.0\~29.9                2184                   14.18                        983                           11.71       1201         17.17   
  ≥30.0                     308                    2.00                         129                           1.54        179          2.56    
  Missing data              6379                   41.43                        3590                          42.76       2789         39.88   

Student\'s *t*‐test.

Chi‐square test.

Fisher\'s exact test.
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Comparison of clinical characteristics {#cam41503-sec-0010}
--------------------------------------

Table [2](#cam41503-tbl-0002){ref-type="table-wrap"} shows significant differences in the occurrence of breast pain (8.33% vs. 9.75%, *P* = 0.002), nipple discharge (2.30% vs. 2.83%, *P* = 0.037), and nipple inversion (1.21% vs. 2.04%, *P* \< 0.0001). Patients in postmenopausal group were more likely to have a positive axillary lymph node status (29.40% vs. 27.95%, *P* = 0.031) and supraclavicular lymph node status (5.85% vs. 4.93%, *P* = 0.007). However, no significant difference in the incidence of distant metastases was observed between the two groups (1.70% vs. 2.10%, *P* = 0.073). Regarding the tumor size, most patients in the two groups had a tumor size between 2 and 5 cm, whereas significantly more patients in premenopausal group had large tumors (8.1% vs. 7.55%, *P* = 0.008).

###### 

Clinical characteristics of the tumors

  Characteristics                     Total (*N* = 15,389)   Premenopausal (*N* = 8395)   Postmenopausal (*N* = 6994)   *P* value                  
  ----------------------------------- ---------------------- ---------------------------- ----------------------------- ----------- ------ ------- -------------------------------------------------
  Breast lump                                                                                                                                      
  Yes                                 14,485                 94.07                        7913                          94.26       6572   93.97   0.482[a](#cam41503-note-0006){ref-type="fn"}
  No                                  904                    5.87                         483                           5.75        421    6.02    
  Breast pain                                                                                                                                      
  Yes                                 1381                   8.97                         699                           8.33        682    9.75    0.002[a](#cam41503-note-0006){ref-type="fn"}
  No                                  14,008                 90.97                        7697                          91.69       6311   90.23   
  Nipple discharge                                                                                                                                 
  Yes                                 391                    2.54                         193                           2.30        198    2.83    0.037[a](#cam41503-note-0006){ref-type="fn"}
  No                                  14,998                 97.40                        8203                          97.71       6795   97.15   
  Nipple inversion                                                                                                                                 
  Yes                                 254                    1.65                         111                           1.32        143    2.04    \<0.0001[a](#cam41503-note-0006){ref-type="fn"}
  No                                  15,135                 98.29                        8285                          98.69       6850   97.94   
  Tumor location in breast                                                                                                                         
  3 o\'clock                          385                    2.50                         214                           2.55        171    2.44    \<0.0001[a](#cam41503-note-0006){ref-type="fn"}
  6 o\'clock                          259                    1.68                         138                           1.64        121    1.73    
  9 o\'clock                          475                    3.08                         254                           3.03        221    3.16    
  12 o\'clock                         813                    5.28                         478                           5.69        335    4.79    
  Upper inner quadrant                1975                   12.83                        1190                          14.18       785    11.22   
  Lower inner quadrant                577                    3.75                         326                           3.88        251    3.59    
  Upper outer quadrant                5637                   36.61                        3238                          38.57       2399   34.30   
  Lower outer quadrant                1119                   7.27                         624                           7.43        495    7.08    
  Nipple--areola                      910                    5.91                         449                           5.35        461    6.59    
  Missing data                        3239                   21.04                        1484                          17.68       1755   25.09   
  Axillary lymph lode status                                                                                                                       
  Positive                            4402                   28.59                        2346                          27.95       2056   29.40   0.031[b](#cam41503-note-0007){ref-type="fn"}
  Negative                            10,097                 65.57                        5578                          66.44       4519   64.61   
  Missing data                        890                    5.78                         471                           5.61        419    5.99    
  Supraclavicular lymph lode status                                                                                                                
  Positive                            823                    5.34                         414                           4.93        409    5.85    0.007[b](#cam41503-note-0007){ref-type="fn"}
  Negative                            13,557                 88.04                        7480                          89.10       6077   86.89   
  Missing data                        1009                   6.55                         501                           5.97        508    7.26    
  Tumor size (cm)                                                                                                                                  
  ≤1                                  820                    5.33                         485                           5.78        335    4.79    0.008[a](#cam41503-note-0006){ref-type="fn"}
  \>1,≤2                              4456                   28.94                        2370                          28.23       2086   29.83   
  \>2,≤5                              7158                   46.49                        3907                          46.54       3251   46.48   
  \>5                                 1208                   7.85                         680                           8.10        528    7.55    
  Missing data                        1747                   11.35                        953                           11.35       794    11.35   
  Distant metastasis                                                                                                                               
  Positive                            290                    1.88                         143                           1.70        147    2.10    0.073[a](#cam41503-note-0006){ref-type="fn"}
  Negative                            14,951                 97.10                        8165                          97.26       6786   97.03   
  Missing data                        148                    0.96                         87                            1.04        61     0.87    

Chi‐square test.

Fisher\'s exact test.
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Comparison of pathological characteristics {#cam41503-sec-0011}
------------------------------------------

Pathological characteristics are displayed in Table [3](#cam41503-tbl-0003){ref-type="table-wrap"}. Regarding ER, PR, human epidermal growth factor receptor‐2 (HER‐2), P53 status and Ki67, with which the patients receiving immunohistochemistry testing presented, we found that patients in premenopausal group were more likely to show positive expression of ER (59.14% vs. 54.86%, *P* \< 0.0001) and PR (55.76% vs. 43.78%, *P* \< 0.0001) than postmenopausal group. Premenopausal patients also had higher proportions of double‐positive expression of ER and PR (i.e., ER+/PR+; 50.46% vs. 40.43%, *P* \< 0.0001) and single‐positive expression of PR (i.e., ER−/PR+; 5.28% vs. 3.33%, *P* \< 0.0001). Conversely, patients in postmenopausal group presented with double‐negative expression of ER and PR (i.e., ER−/PR−; 35.72% vs. 31.40%, *P* \< 0.0001) and single‐positive expression of ER (i.e., ER+/PR−; 14.20% vs. 8.29%, *P* \< 0.0001) more frequently. Moreover, the proportion of patients with a positive HER2 status (14.46% vs. 13.48%, *P* = 0.015) and P53 status (29.47% vs. 25.63%, *P* \< 0.0001) was higher in postmenopausal group. However, no significant difference in the incidence of triple‐negative or Ki67 was observed between the two groups.

###### 

Pathological characteristics of the tumors

  Characteristics                        Total (*N* = 15,389)   Premenopausal (*N* = 8395)   Postmenopausal (*N* = 6994)   *P* value                  
  -------------------------------------- ---------------------- ---------------------------- ----------------------------- ----------- ------ ------- -------------------------------------------------
  Tumor histology                                                                                                                                     
  Carcinoma in situ                      801                    5.20                         413                           4.92        388    5.55    0.053[a](#cam41503-note-0008){ref-type="fn"}
  Invasive carcinoma                     14,008                 90.97                        7712                          91.86       6296   90.02   
  Missing data                           580                    3.77                         270                           3.22        310    4.43    
  Axillary lymph nodes metastasis                                                                                                                     
  Yes                                    6584                   42.76                        3612                          43.03       2972   42.49   0.914[a](#cam41503-note-0008){ref-type="fn"}
  No                                     7210                   46.82                        3962                          47.19       3248   46.44   
  Missing data                           1595                   10.36                        821                           9.78        774    11.07   
  No. of positive axillary lymph nodes                                                                                                                
  0 (N0)                                 7210                   46.82                        3962                          47.19       3248   46.44   0.068[a](#cam41503-note-0008){ref-type="fn"}
  1--3 (N1)                              4125                   26.79                        2285                          27.22       1840   26.31   
  4--9 (N2)                              1572                   10.21                        877                           10.45       695    9.94    
  ≥10 (N3)                               887                    5.76                         450                           5.36        437    6.25    
  Missing data                           1595                   10.36                        821                           9.78        774    11.07   
  Lymphovascular invasion                                                                                                                             
  Yes                                    270                    1.75                         155                           1.85        115    1.64    0.099[a](#cam41503-note-0008){ref-type="fn"}
  No                                     6873                   44.64                        3594                          42.81       3279   46.88   
  Missing data                           8246                   53.55                        4646                          55.34       3600   51.47   
  Tumor grade                                                                                                                                         
  I                                      554                    3.60                         292                           3.48        262    3.75    0.588[a](#cam41503-note-0008){ref-type="fn"}
  II                                     5384                   34.97                        2776                          33.07       2608   37.29   
  III                                    1893                   12.29                        1002                          11.94       891    12.74   
  Uncertain                              1546                   10.04                        785                           9.35        761    10.88   
  Missing data                           5988                   38.89                        3527                          42.01       2461   35.19   
  ER+/PR+                                                                                                                                             
  Yes                                    7269                   50.46                        4236                          40.43       2828   41.25   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     7324                   45.21                        3795                          53.35       3731   52.56   
  Missing data                           796                    4.34                         364                           6.22        435    6.19    
  ER+/PR−                                                                                                                                             
  Yes                                    1722                   8.29                         696                           14.20       993    14.41   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     12,871                 87.21                        7321                          79.40       5553   79.40   
  Missing data                           796                    4.50                         378                           6.41        448    6.19    
  ER−/PR+                                                                                                                                             
  Yes                                    1722                   5.28                         443                           3.33        233    14.41   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     12,871                 90.22                        7574                          90.26       6313   79.40   
  Missing data                           796                    4.50                         378                           6.41        448    6.19    
  ER−/PR−                                                                                                                                             
  Yes                                    4916                   31.40                        2636                          35.72       2498   34.69   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     9677                   64.26                        5395                          58.06       4061   59.12   
  Missing data                           796                    4.34                         364                           6.22        435    6.19    
  HER2 status                                                                                                                                         
  Yes                                    2143                   13.92                        1132                          13.48       1011   14.46   0.015[a](#cam41503-note-0008){ref-type="fn"}
  No                                     8063                   52.36                        4496                          53.56       3567   51.00   
  Uncertain                              2475                   16.07                        1257                          14.97       1218   17.41   
  Missing data                           2708                   17.59                        1510                          17.99       1198   17.13   
  Triple‐negative                                                                                                                                     
  Yes                                    2372                   15.40                        1279                          15.24       1093   15.63   0.502[a](#cam41503-note-0008){ref-type="fn"}
  No                                     13,017                 84.54                        7116                          84.76       5901   84.37   
  P53 status                                                                                                                                          
  Yes                                    4213                   27.36                        2152                          25.63       2061   29.47   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     2304                   14.96                        1060                          12.63       1244   17.79   
  Missing data                           8872                   57.62                        5183                          61.74       3689   52.75   
  Ki67                                                                                                                                                
  ≥14                                    4772                   30.99                        2534                          30.18       2238   32.00   0.715[a](#cam41503-note-0008){ref-type="fn"}
  14                                     2712                   17.61                        1452                          17.30       1260   18.02   
  Missing data                           7905                   51.34                        4409                          52.52       3496   49.99   
  ER status                                                                                                                                           
  Yes                                    8802                   59.14                        4965                          54.86       3837   29.47   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     5816                   36.70                        3081                          39.10       2735   17.79   
  Missing data                           771                    4.16                         349                           6.03        422    52.75   
  PR status                                                                                                                                           
  Yes                                    4772                   55.76                        4681                          43.78       3062   32.00   \<0.0001[a](#cam41503-note-0008){ref-type="fn"}
  No                                     2712                   39.93                        3352                          50.03       3499   18.02   
  Missing data                           7905                   4.31                         362                           6.19        433    49.99   

Chi‐square test.
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Comparison of treatment modes {#cam41503-sec-0012}
-----------------------------

We found that most patients received chemotherapy and that patients in premenopausal group received chemotherapy (85.06% vs. 75.72%, *P* \< 0.0001), radiotherapy (20.31% vs. 13.14%, *P* \< 0.0001), and endocrine therapy (29.77% vs. 22.79%, *P* \< 0.0001) more frequently. Of the 15,389 patients included in the study, 14,521 patients underwent surgery. Patients in premenopausal group were more likely to undergo breast‐conserving surgery, simple mastectomy, and breast reconstruction and were less likely to undergo modified radical mastectomy than patients in postmenopausal group (*P* \< 0.0001). The comparison of the treatment characteristics between the two groups is presented in Table [4](#cam41503-tbl-0004){ref-type="table-wrap"}.

###### 

Treatments of the patients with breast cancer

  Characteristics                           Total (*N* = 15,389)   Premenopausal (*N* = 8395)   Postmenopausal (*N* = 6994)   *P* value                  
  ----------------------------------------- ---------------------- ---------------------------- ----------------------------- ----------- ------ ------- -------------------------------------------------
  Chemotherapy                                                                                                                                           
  Yes                                       12,437                 80.77                        7141                          85.06       5296   75.72   \<0.0001[a](#cam41503-note-0009){ref-type="fn"}
  No                                        2294                   14.90                        960                           11.44       1334   19.07   
  Missing data                              668                    4.34                         294                           3.50        374    5.35    
  Radiotherapy                                                                                                                                           
  Yes                                       2624                   17.04                        1705                          20.31       919    13.14   \<0.0001[a](#cam41503-note-0009){ref-type="fn"}
  No                                        12,058                 78.31                        6373                          75.91       5685   81.28   
  Missing data                              707                    4.59                         317                           3.78        390    5.58    
  Anti‐HER2 therapy                                                                                                                                      
  Yes                                       136                    0.88                         75                            0.89        61     0.87    0.978[a](#cam41503-note-0009){ref-type="fn"}
  No                                        14,571                 94.63                        8018                          95.51       6553   93.69   
  Missing data                              682                    4.43                         302                           3.60        380    5.43    
  Endocrine therapy                                                                                                                                      
  Yes                                       4093                   26.58                        2499                          29.77       1594   22.79   \<0.0001[a](#cam41503-note-0009){ref-type="fn"}
  No                                        10,584                 68.74                        5574                          66.40       5010   71.63   
  Missing data                              712                    4.62                         322                           3.84        390    5.58    
  Type of surgery                                                                                                                                        
  Modified radical mastectomy               11,467                 74.47                        6061                          72.20       5406   77.29   \<0.0001[a](#cam41503-note-0009){ref-type="fn"}
  Breast‐conserving surgery                 1582                   10.27                        986                           11.75       596    8.52    
  Simple mastectomy                         793                    5.15                         451                           5.37        342    4.89    
  Radical mastectomy                        196                    1.27                         115                           1.37        81     1.16    
  Extensive radical mastectomy              103                    0.67                         58                            0.69        45     0.64    
  Breast reconstruction                     380                    2.47                         314                           3.74        66     0.94    
  Missing data                              868                    5.64                         410                           4.88        458    6.55    
  Axillary lymph node dissection                                                                                                                         
  Yes                                       13,065                 84.85                        7145                          85.11       5920   84.64   0.058[a](#cam41503-note-0009){ref-type="fn"}
  No                                        1575                   10.23                        901                           10.73       674    9.64    
  Missing data                              749                    4.86                         349                           4.16        400    5.72    
  Level of axillary lymph node dissection                                                                                                                
  Level I, II                               9504                   61.72                        5220                          62.18       4284   61.25   0.485[a](#cam41503-note-0009){ref-type="fn"}
  Level III                                 1867                   12.12                        1009                          12.02       858    12.27   
  Missing data                              4018                   26.09                        2166                          25.80       1852   26.48   

Chi‐square test.

John Wiley & Sons, Ltd

Multivariate logistic regression analysis of premenopausal breast cancer‐related risk factors among all breast cancer patients {#cam41503-sec-0013}
------------------------------------------------------------------------------------------------------------------------------

Multivariate logistic regression analysis indicated following risk factors were related to premenopausal breast cancer: ethnicity, age at menarche, marital status, number of pregnancies, and number of births. Compared with referent (Han; age at menarche ≤10; married; absence of a history of pregnancy and birth): (1) other ethnicities and number of pregnancy ≥1 were associated with elevated premenopausal breast cancer possibility (OR \> 1, *P* \< 0.05); (2) and increase in age at menarche, never married, widowed/divorced, and number of birth ≥1 were associated with decreased premenopausal breast cancer possibility (OR\<1, *P* \< 0.05) among all breast cancer patients. All the results of multivariate logistic regression analysis are listed in Table [5](#cam41503-tbl-0005){ref-type="table-wrap"}.

###### 

Multivariate logistic regression analysis of premenopausal breast cancer‐related risk factors

  Factors                                          B        S~b~    *χ* ^2^   *P* value   OR (95% CI)
  ------------------------------------------------ -------- ------- --------- ----------- ----------------------
  Ethnicity                                                                               
  Han[a](#cam41503-note-0010){ref-type="fn"}                                              
  Other                                            0.87     0.091   91.048    \<0.001     2.388 (1.997--2.855)
  Age at menarche                                                                         
  ≤10[a](#cam41503-note-0010){ref-type="fn"}                                              
  11--12                                           −1.038   0.413   6.33      0.012       0.354 (0.158--0.795)
  13--14                                           −1.013   0.141   51.852    \<0.001     0.363 (0.276--0.479)
  15--16                                           −0.71    0.133   28.356    \<0.001     0.492 (0.378--0.638)
  17--18                                           −0.6     0.135   19.673    \<0.001     0.549 (0.421--0.716)
  ≥19                                              −0.295   0.143   4.243     0.039       0.745 (0.563--0.986)
  Marital status                                                                          
  Married[a](#cam41503-note-0010){ref-type="fn"}                                          
  Never married                                    −0.88    0.138   40.648    \<0.001     0.415 (0.317--0.544)
  Widowed/ divorced                                −1.832   0.256   51.151    \<0.001     0.16 (0.097--0.264)
  Number of pregnancies                                                                   
  0[a](#cam41503-note-0010){ref-type="fn"}                                                
  1                                                0.49     0.095   26.637    \<0.001     1.632 (1.355--1.965)
  2                                                0.668    0.081   67.892    \<0.001     1.95 (1.664--2.286)
  3                                                0.359    0.078   21.342    \<0.001     1.432 (1.229--1.667)
  Number of births                                                                        
  0[a](#cam41503-note-0010){ref-type="fn"}                                                
  1                                                −2.895   0.214   183.38    \<0.001     0.055 (0.036--0.084)
  2                                                −3.071   0.205   225.333   \<0.001     0.046 (0.031--0.069)
  3                                                −2.496   0.204   149.986   \<0.001     0.082 (0.055--0.123)
  4                                                −1.48    0.208   50.452    \<0.001     0.228 (0.151--0.343)
  ≥5                                               −0.835   0.228   13.392    \<0.001     0.434 (0.278--0.679)

Referent.
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Discussion {#cam41503-sec-0014}
==========

Overall, it is of great interest that a significant difference exists between premenopausal and postmenopausal female breast cancer patients and we found some factors that are associated with elevated or decreased premenopausal breast cancer possibility. The related research is rare.

Consistent with the results of other scholars in China [6](#cam41503-bib-0006){ref-type="ref"}, [14](#cam41503-bib-0014){ref-type="ref"}, the median age at diagnosis was 49.6 years for all breast cancer patients in this study. The premenopausal patients accounted for 54.55% of the total breast cancer cases, the proportion was significantly higher than that of postmenopausal patients, and that differed from the corresponding proportion in a Western population [15](#cam41503-bib-0015){ref-type="ref"}. This finding suggests the possibility that certain differences in the pathogenesis of breast cancer, considered to be related to ethnicity, age at menarche, marital status, number of pregnancies, number of births, and breastfeeding history [16](#cam41503-bib-0016){ref-type="ref"}, [17](#cam41503-bib-0017){ref-type="ref"}, [18](#cam41503-bib-0018){ref-type="ref"}, [19](#cam41503-bib-0019){ref-type="ref"}, may exist between premenopausal and postmenopausal patients.

The onset of the premenopausal peak is considered related to a birth cohort effect, resulting from changes in the menstrual and reproductive patterns and other lifestyle changes [20](#cam41503-bib-0020){ref-type="ref"}, [21](#cam41503-bib-0021){ref-type="ref"}. Further research results in our study supported this possibility. First, multivariate logistic regression analysis indicated that other ethnicities and number of pregnancy ≥1 were associated with elevated premenopausal breast cancer possibility (OR \> 1, *P* \< 0.05). We found a significantly higher proportion of the minority nationalities and times of pregnancy ≥1 in premenopausal women. It was reported that the incidence age of breast cancer of minority nationalities was earlier than that of the Han nationality [22](#cam41503-bib-0022){ref-type="ref"}. Second, multivariate logistic regression analysis showed that increase in age at menarche, never married, widowed/divorced, and number of birth ≥1 were associated with decreased premenopausal breast cancer possibility (OR \< 1, *P* \< 0.05). We found that the age of postmenopausal women experienced menarche was older than that of premenopausal women in this study. Previous studies have suggested that early age at menarche is a risk factor leading to the advanced onset of breast cancer [16](#cam41503-bib-0016){ref-type="ref"}, [23](#cam41503-bib-0023){ref-type="ref"}, [24](#cam41503-bib-0024){ref-type="ref"}. We also noted that a higher proportion of postmenopausal women had more than two births and a history of breastfeeding. A meta‐analysis of 47 studies in 30 countries showed that breastfeeding could reduce the risk of breast cancer [25](#cam41503-bib-0025){ref-type="ref"}. Bao concluded that increased numbers of births per woman were associated with a reduced risk of breast cancer for postmenopausal women [17](#cam41503-bib-0017){ref-type="ref"}. We found the number of pregnancies was positively associated with risk of premenopausal breast cancer, but increased number of births decreased the risk of that. Because of the one‐child policy and some other reasons, Chinese women may not to give a birth after pregnancy. Here come to a conclusion that only pregnancy but no childbirth might increase the risk of premenopausal breast cancer. We speculate that the fall in the fertility rate [26](#cam41503-bib-0026){ref-type="ref"}, [27](#cam41503-bib-0027){ref-type="ref"}, early menarche age, the married and less breastfeeding might have increased the possibility of premenopausal breast cancer.

A Westernized lifestyle, particularly an increase in the obesity prevalence and physical inactivity in recent decades, is likely to affect the observed rise in breast cancer incidence [28](#cam41503-bib-0028){ref-type="ref"}, [29](#cam41503-bib-0029){ref-type="ref"}. Obesity was considered a mechanism of breast cancer in postmenopausal women [30](#cam41503-bib-0030){ref-type="ref"}. These results guide postmenopausal women to adjust their diet, strengthen exercises, and reduce the risk factors of breast cancer that can be controlled artificially.

Breast cancer is age‐dependent, and it is widely accepted that young women tend to present with a greater tumor size that is more advanced and with poorer prognostic characteristics [31](#cam41503-bib-0031){ref-type="ref"}, [32](#cam41503-bib-0032){ref-type="ref"}. We found that premenopausal women presented with a greater tumor size (more than 2 cm) than postmenopausal women in our study. The fact might imply there are also more aggressive breast cancers in Chinese premenopausal patients than in postmenopausal.

We further analyzed the difference in the pathological features between the two groups. The ER and PR status are important indicators to guide endocrine therapy in breast cancer. It is also an important factor affecting the prognosis of breast cancer [33](#cam41503-bib-0033){ref-type="ref"}, [34](#cam41503-bib-0034){ref-type="ref"}. Wittliff studied the relationship between menopausal status and ER and reported that the positive expression of ER occurred at a rate of 45% in premenopausal women and at a rate of \<63% in postmenopausal patients [35](#cam41503-bib-0035){ref-type="ref"}. Anderson reported that ER‐positive rates rose continuously irrespective of menopause [36](#cam41503-bib-0036){ref-type="ref"}. However, we found the opposite. That is, the positive expression of ER occurred at a rate of 59% in premenopausal women and was higher than 55% in postmenopausal patients. We also found that postmenopausal patients had higher proportions of positive HER2 expression and positive P53 expression. Scholars have reported a negative correlation between the positive expression of ER and positive HER2 status [37](#cam41503-bib-0037){ref-type="ref"}, [38](#cam41503-bib-0038){ref-type="ref"}. We obtained similar results. Those results are similar to that in another article from the same database [32](#cam41503-bib-0032){ref-type="ref"}. Additionally, higher proportion of (ER+/PR+) in premenopausal patients and higher proportion of (ER−/PR−) in postmenopausal patients suggested that the distribution of hormone receptors in western Chinese women is different from that in foreign countries. The reasons for the difference in the expression of hormone receptor may be as follows: (1) the proportion of premenopausal and postmenopausal women with breast cancer in China is opposite of that in foreign countries [15](#cam41503-bib-0015){ref-type="ref"}; (2) the stimulation of different human populations and the external environment affect the expression of hormone receptor; and (3) pregnancy and childbirth lead to the fluctuation of estrogen and progesterone levels, which affect the expression of hormone receptor. The relationship between menopause and ER and PR remains controversial, and we need more large‐scale studies to clarify their relationship.

Regarding treatment options, we compared the following five aspects between the two groups: surgery, chemotherapy, radiotherapy, endocrine therapy, and anti‐HER2 therapy. First, we found that 94% of all patients underwent surgery. Regarding the choice of surgical approach, a higher proportion of premenopausal patients underwent advanced operation methods, such as breast‐conserving surgery and breast reconstruction. A possible explanation was that younger patients have a greater desire to keep their original breasts and shapes and are more accepting of advanced operation methods compared to postmenopausal patients [39](#cam41503-bib-0039){ref-type="ref"}. Second, we found that there are more premenopausal patients receiving chemotherapy. Chemotherapy is one of the most commonly used and most effective methods among adjuvant therapies for treating breast cancer. Premenopausal patients had a smaller average age, higher malignancy, and risk of recurrence of the tumors [32](#cam41503-bib-0032){ref-type="ref"}, and it was reported that chemotherapy can significantly reduce the risk of relapse of high malignant breast cancer [34](#cam41503-bib-0034){ref-type="ref"}, [40](#cam41503-bib-0040){ref-type="ref"}, so they could benefit more from chemotherapy. The discovery of more aggressive cancers found in premenopausal women is the fact that leads to more chemotherapy in this population. Third, we found that a higher proportion of premenopausal patients receiving radiotherapy, as radiotherapy is necessary after breast‐conserving surgery, and that the proportion of premenopausal patients receiving breast‐conserving surgery were higher. Additionally, adjuvant radiotherapy after surgery significantly reduces the local recurrence rate and increases the overall survival rate [41](#cam41503-bib-0041){ref-type="ref"}. Similarly, the proportion of premenopausal patients receiving endocrine therapy was significantly higher than that of postmenopausal patients. The increased use of endocrine therapy may be due to the fact that endocrine therapy is suitable for hormone receptor‐positive breast cancer and significantly reduces the recurrence rate [42](#cam41503-bib-0042){ref-type="ref"}, and the proportion of (ER+/PR+) in premenopausal patients was significantly higher. Finally, this study showed that very few patients with a positive HER2 status accepted anti‐HER2 therapy. The possible reason may be that the HER2 testing condition is deficient in local areas. Additionally, anti‐HER2 therapy is not included in health care, indicating that it is a costly burden in western China.

Limitations {#cam41503-sec-0015}
-----------

Our study had some limitations. First, all patients included were from nine provinces of western China; thus, the results may not be generalizable to all women in China. Second, data regarding some characteristics, such as HER2 status, BMI, breastfeeding history, tumor location, P53 status, and Ki67 status, were missing, which may have underpowered the study. Another limitation is that we failed to follow up the patients. As a result, we cannot analyze the relationship between prognosis and clinicopathologic features.

Conclusion {#cam41503-sec-0016}
==========

In this study, we found that the fall in the fertility rate, early menarche age, married, and less breastfeeding might have increased the possibility of premenopausal breast cancer. Significant differences exist in the tumor size, hormone receptor state, HER2 expression, epidemiological features, and treatment modes between premenopausal and postmenopausal female breast cancer patients in western China. The difference in breast cancer onset period remains to be investigated in the further studies.
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